Literature DB >> 15734199

Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS.

Mahmoud Toulany1, Klaus Dittmann, Michael Baumann, H Peter Rodemann.   

Abstract

BACKGROUND AND
PURPOSE: To investigate the cellular and molecular consequences of antagonizing radiation-induced EGFR-activation in vitro. PATIENTS AND METHODS: The effect of the EGFR tyrosine kinase inhibitor BIBX1382BS on radiation sensitivity was determined after single- and fractionated-dose irradiation in human cell lines of bronchial carcinoma (A549), breast adeno-carcinoma (MDA-MB-231), pharyngeal squamous-cell carcinoma (FaDu), squamous-cell carcinoma of cervix (HTB-35) as well as normal (HSF-7) and transformed (HH4-DED) human skin fibroblasts. Applying immuno-precipitation and western blotting pattern of radiation-dependent activation of different components of EGFR-signaling after pre-treatment with and without BIBX1382BS or other tyrosine kinase inhibitors was analyzed.
RESULTS: Autophosphorylation of EGFR which occurred 1-5 min after irradiation (IR, 2 Gy) or treatment with EGF (100 ng/ml) could be inhibited in all cells tested by pre-treatment with BIBX1382BS for 30 min. Combination of drug treatment with fractionated irradiation (4x2 Gy) led to a strong radiosensitizing effect in Ras-mutated A549 and MDA-MB-231 cells, but not in normal Ras presenting cell lines FaDu and HTB-35 or normal and transformed human skin fibroblasts. Both BIBX1382BS as well as the PI3 kinase inhibitor LY294002 led to a blockage (for A549 cells) or reduction (for FaDu cells) of radiation-induced P-AKT. In contrast to FaDu cells, treatment of A549 cells with LY294002 resulted in a significant decrease of post-irradiation survival of A549 cells. Furthermore, only in Ras-mutated cells, but not in normal Ras cells clonogenic survival and phosphorylation of AKT was sensitive to pre-treatment with TGF-alpha-neutralizing antibody indicating an important role of TGF-alpha in regulating radiation-induced EGFR signaling.
CONCLUSIONS: Enhancement of radiation sensitivity by the specific EGFR-tyrosine kinase inhibitor BIBX1382BS is not generally achieved in human tumor cells, but depends most likely on the Ras genotype of the cell lines tested.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15734199     DOI: 10.1016/j.radonc.2004.11.008

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  22 in total

1.  Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer.

Authors:  Flavien Devun; Guilhem Bousquet; Julian Biau; Aurélie Herbette; Christophe Roulin; Frédérique Berger; Jian-Sheng Sun; Sylvie Robine; Marie Dutreix
Journal:  J Gastroenterol       Date:  2011-11-09       Impact factor: 7.527

2.  Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.

Authors:  M Saki; M Toulany; W Sihver; M Zenker; J-M Heldt; B Mosch; H-J Pietzsch; M Baumann; J Steinbach; H P Rodemann
Journal:  Strahlenther Onkol       Date:  2012-08-10       Impact factor: 3.621

3.  ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.

Authors:  Mahmoud Toulany; Minjmaa Minjgee; Mohammad Saki; Marina Holler; Friedegund Meier; Wolfgang Eicheler; H Peter Rodemann
Journal:  Cancer Biol Ther       Date:  2013-12-09       Impact factor: 4.742

4.  Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo.

Authors:  Kristin Gurtner; Zofia Kryzmien; Lydia Koi; Meng Wang; Cyril H Benes; Sandra Hering; Henning Willers; Michael Baumann; Mechthild Krause
Journal:  Int J Cancer       Date:  2019-08-19       Impact factor: 7.396

Review 5.  New insights into the regulation of the actin cytoskeleton by tropomyosin.

Authors:  C-L Albert Wang; Lynne M Coluccio
Journal:  Int Rev Cell Mol Biol       Date:  2010       Impact factor: 6.813

6.  Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study.

Authors:  Agata I Rembielak; Pooja Jain; Andrew S Jackson; Melanie M Green; Gillian R Santorelli; Gillian A Whitfield; Adrian Crellin; Angel Garcia-Alonso; Ganesh Radhakrishna; James Cullen; M Ben Taylor; Ric Swindell; Catharine M West; Juan Valle; Azeem Saleem; Patricia M Price
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

7.  Hypoxia regulates insulin receptor substrate-2 expression to promote breast carcinoma cell survival and invasion.

Authors:  Katerina Mardilovich; Leslie M Shaw
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

8.  Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma.

Authors:  Ipsita Pal; Kaushik Kumar Dey; Madhuri Chaurasia; Sheetal Parida; Subhayan Das; Y Rajesh; Kulbhushan Sharma; Tamohan Chowdhury; Mahitosh Mandal
Journal:  Tumour Biol       Date:  2015-12-02

9.  Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.

Authors:  Florence Huguet; Marie Fernet; Nicole Giocanti; Vincent Favaudon; Annette K Larsen
Journal:  Target Oncol       Date:  2016-06       Impact factor: 4.493

Review 10.  Molecular targets for tumor radiosensitization.

Authors:  Philip J Tofilon; Kevin Camphausen
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.